ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Creative Planning

Creative Planning boosted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 7.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,263 shares of the company’s stock after purchasing an additional 2,307 shares during the period. Creative Planning’s holdings in ARS Pharmaceuticals were worth $511,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in SPRY. Russell Investments Group Ltd. acquired a new stake in ARS Pharmaceuticals during the first quarter valued at approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ARS Pharmaceuticals by 151.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in shares of ARS Pharmaceuticals in the 2nd quarter valued at approximately $87,000. Paloma Partners Management Co purchased a new stake in shares of ARS Pharmaceuticals in the 1st quarter valued at approximately $103,000. Finally, SG Americas Securities LLC purchased a new stake in shares of ARS Pharmaceuticals in the 1st quarter valued at approximately $119,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ARS Pharmaceuticals

In other news, insider Eric Karas sold 10,000 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 5,693 shares in the company, valued at $79,702. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Eric Karas sold 10,000 shares of the stock in a transaction on Monday, August 19th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the transaction, the insider now owns 5,693 shares in the company, valued at $79,702. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Brian Dorsey sold 50,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $15.00, for a total transaction of $750,000.00. Following the transaction, the chief operating officer now owns 6,024 shares in the company, valued at approximately $90,360. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,055,895 shares of company stock worth $14,619,032 in the last 90 days. 40.10% of the stock is owned by insiders.

ARS Pharmaceuticals Stock Up 0.8 %

SPRY stock opened at $15.32 on Wednesday. ARS Pharmaceuticals, Inc. has a 12-month low of $3.38 and a 12-month high of $17.08. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -32.60 and a beta of 0.90. The company has a 50 day moving average of $14.09 and a two-hundred day moving average of $11.30.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. On average, research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

SPRY has been the subject of several research analyst reports. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research report on Friday, September 20th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, ARS Pharmaceuticals presently has an average rating of “Buy” and an average target price of $24.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.